Abstract
CTP:phosphocholine cytidylyltransferase (CCT), an amphitropic enzyme that regulates phosphatidylcholine synthesis, is composed of a catalytic head domain and a regulatory tail. The tail region has dual functions as a regulator of membrane binding/enzyme activation and as an inhibitor of catalysis in the unbound form of the enzyme, suggesting conformational plasticity. These functions are well conserved in CCTs across diverse phyla, although the sequences of the tail regions are not. CCT regulatory tails of diverse origins are composed of a long membrane lipid-inducible amphipathic helix (m-AH) followed by a highly disordered segment, reminiscent of the Parkinson disease-linked protein, α-synuclein, which we show shares a novel sequence motif with vertebrate CCTs. To unravel features required for silencing, we created chimeric enzymes by fusing the catalytic domain of rat CCTα to the regulatory tail of CCTs from Drosophila, Caenorhabditis elegans, or Saccharomyces cerevisiae or to α-synuclein. Only the tail domains of the two invertebrate CCTs were competent for both suppression of catalytic activity and for activation by lipid vesicles. Thus, both silencing and activating functions of the m-AH can tolerate significant changes in length and sequence. We identified a highly amphipathic 22-residue segment in the m-AH with features conserved among animal CCTs but not yeast CCT or α-synuclein. Deletion of this segment from rat CCT increased the lipid-independent V(max) by 10-fold, equivalent to the effect of deleting the entire tail, and severely weakened membrane binding affinity. However, membrane binding was required for additional increases in catalytic efficiency. Thus, full activation of CCT may require not only loss of a silencing conformation in the m-AH but a gain of an activating conformation, promoted by membrane binding.
Highlights
The mechanism whereby CTP:phosphocholine cytidylyltransferase (CCT) is auto-inhibited by its membrane-induced amphipathic helix (m-AH) is unknown
CCT regulatory tails of diverse origins are composed of a long membrane lipid-inducible amphipathic helix (m-AH) followed by a highly disordered segment, reminiscent of the Parkinson disease-linked protein, ␣-synuclein, which we show shares a novel sequence motif with vertebrate CCTs
We have shown that the tail region, starting from residue 237 or 226 (C. elegans) to the C terminus, can fold independently of the catalytic domain when presented to lipid vesicles [16]
Summary
The mechanism whereby CCT is auto-inhibited by its membrane-induced amphipathic helix (m-AH) is unknown. Yang et al [15] found that rat CCT␣ truncated at the boundary between the catalytic and M domain or truncated one-third of the way into domain M resulted in a very slow enzyme, leading them to suggest that rather than acting as a silencer of catalysis, domain M in its membrane-bound state functions as a positive regulator of activity. These models are not mutually exclusive, the conflicting results from very similar truncation variants need resolution. We initially asked three questions: Is the predicted structure (or lack of it) in this region conserved? Is there strong binding between the catalytic and M domains in the lipid-free form? Can the M domain of a CCT lacking a repeated 11-mer motif substitute for the native M domain in mammalian CCT with respect to silencing or activation? These explorations led to the identification of a conserved segment within domain M that is a key contributor to its silencing and activation functions
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.